---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-25-000022"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:59:06.587611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025

## Summary
- Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.
- Raised $230M in November 2024 public offering; Q4 net cash used in operations $37.2M.
- Interim Phase 1 data for SPY001 (α4β7) shows half-life >90 days supporting Q6M dosing; Phase 2 UC trial mid-2025.
- SPY002 (TL1A) Phase 1 interim data expected Q2 2025; Phase 2 RA trial initiation mid-2025; top-line 2026.
- SPY003 (IL-23) FIH trial starts Q1 2025 with interim data H2 2025; Phase 2 platform trial mid-2025.

## SEC filing metadata
- accession: 0001636282-25-000022
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/0001636282-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/syre-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-25-000022
- JSON: https://secwatch.observer/filing/0001636282-25-000022.json
- Plain text: https://secwatch.observer/filing/0001636282-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.